Guy Parmelin: Swiss Businesses Plan $29 Billion Investment in India
- Swiss businesses plan to pump $29 billion into India through past, announced, and targeted investments running up to 2030, Swiss Economic Minister Guy Parmelin announced in New Delhi,...
- Parmelin outlined the figures during a visit to India, citing a survey conducted by the Swiss-Indian Chamber of Commerce.
- Parmelin noted that the ministerial visit aims to address practical obstacles faced by specific industries, pointing to bureaucratic red tape and dividend taxation.
Swiss businesses plan to pump $29 billion into India through past, announced, and targeted investments running up to 2030, Swiss Economic Minister Guy Parmelin announced in New Delhi, according to reporting by Keystone-SDA.
EFTA targets 100 billion dollars in investments
Parmelin outlined the figures during a visit to India, citing a survey conducted by the Swiss-Indian Chamber of Commerce. The combined capital encompasses investments made last year alongside commitments slated for the remainder of the decade. The broader objective for the European Free Trade Association—comprising Switzerland, Liechtenstein, Norway, and Iceland—reaches for $100 billion in investments over a 15-year window. Parmelin stated that the initiative remains on schedule and projects the creation of 400,000 direct and indirect jobs by 2030.
Swiss officials seek to resolve trade obstacles
Despite the high capital volume, economic hurdles persist. Parmelin noted that the ministerial visit aims to address practical obstacles faced by specific industries, pointing to bureaucratic red tape and dividend taxation. Resolving taxation issues requires updates to the existing trade agreement between India and EFTA nations. Swiss officials seek to secure a reliable investment protection agreement featuring dependable arbitration and legal pathways for resolving business disputes with the Indian state.
India works to align pharmaceutical standards
Discussions in New Delhi also touch upon intellectual property rights within the pharmaceutical sector. India functions as the “generics factory of the world” while working to enhance its own domestic innovation protections. Parmelin acknowledged that aligning Indian practices with Swiss standards—such as clinical trial safety regulations—will take time, though significant progress has already unfolded.
Bilateral meetings in New Delhi
Parmelin confirmed that the three-day diplomatic trip provides Swiss enterprises a direct platform to air friction points. A scheduled meeting with India’s finance minister addresses investment protection and dispute resolution frameworks directly. These three days stehen den Schweizer Unternehmen zur Verfügung, um die Reibungspunkte auf den Tisch zu bringen,
Parmelin said.
